Left Atrial Appendage Occlusion Versus NOACs in patients With Atrial Fibrillation: Rationale and Design of the CATALYST Trial

Key Points

• Left atrial appendage occlusion may provide advantages over NOACs for managing atrial fibrillation.
• The CATALYST trial is designed to evaluate this comparison in clinical settings.
• Participants will be monitored for effectiveness and safety across various treatment groups.
• The findings could lead to better treatment strategies in atrial fibrillation patients.